Biophytis S.A.

ALBPS

FR001400OLP5

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 14:38:14 16/07/2024 BST			5-day change	1st Jan Change
0.57 ^EUR	0.00%		-0.35%	-72.06%

07-12	BIOPHYTIS : Invest Securities confirms its recommendation	CF
07-11	Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Biophytis S.A.

BIOPHYTIS : Invest Securities confirms its recommendation	07-12	CF
Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	07-11	MT
Biophytis: approval for a clinical trial in the USA	07-11	CF
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity	07-11	CI
Biophytis SA Presents Roll-Out and Results of Its Phase 2-3 Cova Study Results in Severe Forms of Covid-19 At the World Congress on Infectious Diseases	07-01	CI
Biophytis: cash position strengthened, share price soars	06-20	CF
Biophytis Extends Bond Financing Deal with Investment Fund Atlas	06-20	MT
Biophytis S.A. Grants Blanver Exclusive Rights to Bio101 in Latin America in Deal Valued At Up to ?108 Million	06-20	CI
Biophytis S.A. Announces the Successful Industrial Transfer of Bio101 (20-Hydroxyecdysone) Production by Its Service Provider Seqens	06-14	CI
Biophytis Files Investigational New Drug Application with US FDA for Mid-stage Obesity Drug Trial	06-10	MT
Biophytis: application filed in obesity in the USA	06-10	CF
Biophytis SA Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity	06-10	CI
Biophytis unveils design for obesity study	05-14	CF
Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity	05-14	CI

Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19. The company is located in Paris, France and Cambridge, Massachusetts.

Sector

Biotechnology & Medical Research

Calendar

28/10/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOPHYTIS S.A.	-72.06%	3.27M
VERTEX PHARMACEUTICALS INCORPORATED	+21.40%	127B
REGENERON PHARMACEUTICALS, INC.	+23.75%	117B
ARGENX SE	+26.23%	27.67B
BIONTECH SE	-19.79%	20.33B
GENMAB A/S	-16.01%	16.79B
BEIGENE, LTD.	-18.56%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+13.37%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+58.74%	14.43B